NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis $1.41 +0.01 (+0.79%) As of 10:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Cadrenal Therapeutics Stock (NASDAQ:CVKD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cadrenal Therapeutics alerts:Sign Up Key Stats Today's Range$1.34▼$1.5350-Day Range$0.87▼$1.5152-Week Range$0.82▼$12.50Volume17,775 shsAverage Volume183,525 shsMarket Capitalization$5.04 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingHold Company Overview Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing treatments to prevent blood clots in people with cardiovascular conditions that require long-term anticoagulation. Its pipeline centers on tecarfarin, an investigational oral anticoagulant being developed as a potential alternative to warfarin. Tecarfarin is designed to be processed through a different metabolic pathway than warfarin and is being studied for patients with needs such as mechanical heart valves and end-stage renal disease. It is not an approved medicine, and the company does not currently market a commercial product.AI Generated. May Contain Errors. Read More Cadrenal Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCVKD MarketRank™: 2.654984733835 of 5 starsCadrenal Therapeutics scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCadrenal Therapeutics has a consensus price target of $13.00, representing about 818.7% upside from its current price of $1.42.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($3.86) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.57% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 3.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently decreased by 18.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment1.82 News SentimentCadrenal Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cadrenal Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.59% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVKD Stock News HeadlinesCadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on MondayNovember 8, 2026 | americanbankingnews.comCadrenal Therapeutics IncOctober 27, 2026 | markets.ft.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)Cadrenal Therapeutics Begins Strategic Review Following FDA Alignment On CAD-1005October 7, 2026 | rttnews.comCadrenal Therapeutics Begins Strategic Review of Orphan PortfolioOctober 7, 2026 | tipranks.comCadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory TherapeuticsOctober 7, 2026 | globenewswire.comCadrenal Shareholders Approve Equity Plan and Board ChangesSeptember 29, 2026 | tipranks.comCadrenal Therapeutics CEO to Present at Lytham Partners Fall 2026 Investor Conference September 21, 2026 | quiverquant.comQSee More Headlines CVKD Stock Analysis - Frequently Asked Questions How have CVKD shares performed this year? Cadrenal Therapeutics' stock was trading at $6.78 at the start of the year. Since then, CVKD stock has decreased by 79.1% and is now trading at $1.4150. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.91) by $0.60. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share. Who are Cadrenal Therapeutics' major shareholders? Cadrenal Therapeutics' top institutional shareholders include Courier Capital LLC (1.11%). View institutional ownership trends. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cadrenal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Palantir Technologies (PLTR), Tesla (TSLA), NVIDIA (NVDA), Invesco QQQ (QQQ), Walt Disney (DIS), Oracle (ORCL) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/13/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CVKD's financial health is in the Red zone, according to TradeSmith. CVKD has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CVKD CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees5Year Founded2022Price Target and Rating Average Price Target for Cadrenal Therapeutics$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+812.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-406.41% Return on Assets-273.80% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.22Miscellaneous Outstanding Shares3,570,000Free Float3,047,000Market Cap$5.09 million OptionableNot Optionable Beta1.94 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CVKD) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.